Methodological review

How is access to incretin-based obesity pharmacotherapy distributed, and what does the pattern of unregulated supply indicate about it?

To what extent does a change in body weight predict a change in the clinical outcomes for which weight reduction is undertaken?

What is known about the direction and magnitude of the difference between sponsor-conducted and independently conducted trials, and how should an evidence body treat a class whose entire evidence base is sponsor-generated?

Are the trials in the incretin evidence network sufficiently similar to support indirect comparison?

What can be concluded from a development programme that was discontinued, and how should the Institute record it?

For neuropeptides holding a national marketing registration outside the jurisdictions the Institute routinely reviews, what evidence is retrievable and what can be concluded from it?